Benjamin Kopp, MD, MPH

Co-Director, C3 Immune Core
Email

Amal Amer, MD, PhD

Co-Director, C3 Immune Core
​Email

Persons with CF are prone to chronic infections and hyperinflammatory responses, which are associated with progressive tissue damage. It is now recognized that chronic infection and inflammation results from intrinsically dysfunctional immune cells. Therefore, the overarching goals of the C3 Immune Core are to provide a unified source of fresh immune cells to investigators, deliver reproducible data, and enable training of students and fellows in CF immune cell functions. C3IC services support projects and C3 members who seek to understand complex CF host-pathogen interactions and inflammation and thereby develop novel therapeutic strategies that prevent the establishment of chronic infections and tissue destruction.

Request Specimens

Facilitates Research Through:

1. Isolation and analysis of fresh blood immune cells (neutrophils, lymphocytes, peripheral blood monocyte-derived macrophages), fresh bronchoalveolar lavage-derived immune cells, and fresh sputum-derived immune cells;
2. Critical assays of immune function including comprehensive cell counts, cytokine/chemokine production, and Enzyme-Linked ImmunoSpot (ELISpot) assays from immune cells at baseline and in response to infections or treatments;
3. Functional analysis including halide efflux and patch-clamp electrophysiology for CFTR and other ion channels within immune cells; and
4. ​Access and assistance with interpretation of state of the art ‘omics assays (single-cell RNA-Seq, mi-RNA-Seq, Methyl-Seq, CyTOF, metabolomics, proteomics) in immune cells.

Acknowledging C3IC

Publish Results
Publications resulting from studies supported by C3IC should include the following acknowledgement:

This work was supported in part by the Cure CF Columbus Immune Core (C3IC). The members of the C3IC include: Drs. Benjamin Kopp, Amal Amer, Victoria Best, Santiago Partida-Sanchez, and Estelle Cormet-Boyaka. C3IC is supported by the Division of Pediatric Pulmonary Medicine and the C3 Translational Core. Grant support provided by The Ohio State University Center for Clinical and Translational Science (National Center for Advancing Translational Sciences, Grant UL1TR002733) and by the Cystic Fibrosis Foundation (Research Development Program, Grant MCCOY19RO – Core C [Kopp]).

Resources:

Kopp Lab
​Nationwide Children's Flow Cytometry Core